abstract |
The present invention provides human monoclonal antibodies directed against B7-H1 and the use of these antibodies in the diagnosis of and for the treatment of diseases associated with B7-H1 activity and / or expression. An isolated antibody or antigen-binding fragment thereof that specifically binds to B7-H1. The antibody is a monoclonal antibody comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR and VL CDR, each having a specific amino sequence. An antibody or antigen-binding fragment thereof that inhibits the growth of a human cancer cell line in a xenograft model as compared to an isotype control antibody. A pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier. [Selection figure] None |